US EditionPublished • loading... • Updated
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International ...
Icovamenib showed durable HbA1c reductions up to 1.5% at 52 weeks in type 2 diabetes patients with severe insulin deficiency, maintaining a favorable safety profile.
Summary by Enid News & Eagle
10 Articles
10 Articles
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib - Biomea Fusion (NASDAQ:BMEA)
Biomea Fusion (NASDAQ: BMEA) shares rose Friday after the company reported positive Phase II data for icovamenib in type 2 diabetes, highlighting durable efficacy and a favorable safety profile.
·New York, United States
Read Full Article
Hastings TribuneReposted by 
Enid News & Eagle
Enid News & EagleBiomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International ...
SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Juan Pablo Frías, MD, delivered an oral presentation at the 19th…
·Nebraska, United States
Read Full Article
Coverage Details
Total News Sources10
Leaning Left1Leaning Right1Center5Last UpdatedBias Distribution72% Center
Bias Distribution
- 72% of the sources are Center
72% Center
14%
C 72%
14%
Factuality
To view factuality data please Upgrade to Premium
